Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05896228 · ClinicalTrials.gov registry record · Phase 2

Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

A Phase 2 study of Refractory Multiple Myeloma and Relapsed Multiple Myeloma, sponsored by Benjamin T Diamond, MD.

Recruiting
Registry status
Phase 2
Development phase
30
Enrollment target
1
Study location

NCT05896228 is a Phase 2 study of Refractory Multiple Myeloma and Relapsed Multiple Myeloma that is actively recruiting participants, run by Benjamin T Diamond, MD. The registered enrollment target is 30 participants, below the 48-participant average among 67 other Refractory Multiple Myeloma trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05896228, a Phase 2 study of Refractory Multiple Myeloma and Relapsed Multiple Myeloma, is actively recruiting participants, sponsored by Benjamin T Diamond, MD.

RECRUITING
Registry status
Phase 2
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The investigators want to find out whether or not giving patients who have relapsed or refractory multiple myeloma (MM) the experimental medication combination iberdomide, carfilzomib, daratumumab, and dexamethasone (Iber-KDd) may produce better results than the current (standard of care) treatments. This study will examine the tolerability and efficacy of this combination therapy for all participants and the ability of this combination therapy to shrink or prevent MM from returning.

Conditions Studied

Refractory Multiple Myeloma Relapsed Multiple Myeloma

Interventions

  • DRUG Acetaminophen
  • DRUG Dexamethasone
  • DRUG Daratumumab
  • DRUG Iberdomide
  • DRUG Carfilzomib

Study Locations (1)

Florida

  • University of Miami - Miami

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-02-20
Est. Completion 2031-03-01
Phase Phase 2

Sponsor

Benjamin T Diamond, MD

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05896228

The ClinicalTrials.gov registry entry for NCT05896228 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 48-participant average among 67 other Refractory Multiple Myeloma trials with a reported enrollment target (37% lower). The listed sponsor is Benjamin T Diamond, MD, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Refractory Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Acetaminophen is the first listed.

NCT05896228 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT05896228 about?

NCT05896228 is a clinical study titled "Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma". The investigators want to find out whether or not giving patients who have relapsed or refractory multiple myeloma (MM) the experimental medication combination iberdomide, carfilzomib, daratumumab, and dexamethasone (Iber-KDd) may produce better results than the current (standard of care) treatments...

What is the current status of trial NCT05896228?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2024-02-20. Estimated completion is 2031-03-01.

What conditions does trial NCT05896228 study?

This clinical trial studies the following conditions: Refractory Multiple Myeloma, Relapsed Multiple Myeloma.

What interventions are being tested in trial NCT05896228?

The interventions under investigation include: Acetaminophen (DRUG), Dexamethasone (DRUG), Daratumumab (DRUG), Iberdomide (DRUG), Carfilzomib (DRUG).

Who is sponsoring clinical trial NCT05896228?

This trial is sponsored by Benjamin T Diamond, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05896228 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Refractory Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Refractory Multiple Myeloma

All registered trials for this condition

Relapsed Multiple Myeloma

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.